15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | — | -$14M | — | — | -$7M | — | $2M |
| 2024 | $582000 | -$45M | 83.5% | -2693.1% | -$16M | — | $2M |
| 2023 | $68000 | -$22M | -247.1% | -31080.9% | -$20M | — | $12M |
| 2022 | $0 | -$25M | — | — | -$21M | — | $16M |
| 2021 | — | -$123M | — | — | -$24M | — | $17M |
| 2020 | $6M | -$7M | 0.0% | -125.0% | -$8M | $2M | $2M |
| 2019 | $20M | -$2M | 0.0% | -8.9% | $3M | — | $5M |
| 2018 | $23M | -$259000 | 0.0% | 0.9% | $717000 | $4M | $3M |
| 2017 | $21M | -$1M | 0.0% | -6.6% | -$179000 | $5M | $3M |
| 2016 | $22M | -$3M | 0.0% | -10.2% | -$404000 | $8M | $6M |
| 2015 | $25M | -$7M | 0.0% | -28.1% | -$5M | $7M | — |
| 2014 | $26M | -$5M | 0.0% | -18.2% | — | $5M | — |
| 2013 | $24M | -$1M | 0.0% | -4.7% | — | $2M | — |
| 2012 | — | -$995000 | — | — | $930000 | — | — |
| 2011 | — | -$3M | — | — | -$1M | — | — |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | — | -$6M | — | — | -$2M | — | $9M |
| Dec '25 | — | -$2M | — | — | -$1M | — | $2M |
| Sep '25 | — | -$1M | — | — | — | — | $3M |
| Jun '25 | — | -$3M | — | — | — | — | $4M |
| Mar '25 | — | -$8M | — | — | — | — | $2M |
| Dec '24 | $1000 | -$6M | 100.0% | -269700.0% | -$4M | — | $2M |
| Sep '24 | $487000 | -$27M | 112.3% | -463.9% | -$6M | — | $4M |
| Jun '24 | $47000 | -$6M | -102.1% | -10491.5% | -$3M | — | $7M |
| Mar '24 | $47000 | -$7M | -29.8% | -12312.8% | -$4M | — | $9M |
| Dec '23 | $17000 | -$6M | -288.2% | -33911.8% | -$5M | — | $12M |
| Sep '23 | $51000 | -$6M | -135.3% | -10794.1% | -$6M | — | $9M |
| Jun '23 | — | -$5M | — | — | -$4M | — | $6M |
| Mar '23 | $0 | -$5M | — | — | -$6M | — | $9M |
| Dec '22 | $0 | -$4M | — | — | -$5M | — | $16M |
| Sep '22 | $0 | -$7M | — | — | -$6M | — | $13M |
| Jun '22 | — | -$3M | — | — | -$4M | — | $19M |
| Mar '22 | — | -$9M | — | — | -$5M | — | $24M |
| Dec '21 | — | -$8M | — | — | -$7M | — | $17M |
| Sep '21 | — | -$86M | — | — | -$6M | — | $24M |
| Jun '21 | — | -$10M | — | — | -$7M | — | $50M |
How the market has priced ERNA against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Ernexa Therapeutics Inc.'s revenue has declined 50.6% per year. These are computed facts, not advice.
As of FY2025, Ernexa Therapeutics Inc. reported — of total debt against $2M of cash; operating income covered interest expense 93×.
In FY2025, gross margin was —, operating margin —, and net margin —.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.